Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome

A technology for amphetamines and dependence disorders, applied in the field of medical drugs, can solve problems such as abuse, lack of simultaneous treatment, and unsatisfactory drug efficacy, and achieve the effect of controlling withdrawal symptoms

Active Publication Date: 2010-09-15
卢正堂 +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are some therapeutic drugs on the market, but the curative effect is not satisfactory, and all of them can only treat the dependence of a certain substance of abuse
However, the problem of multi-drug or multi-substance abuse is common. For example, in my country, in recent years, mixed dependence on amphetamine-type stimulants and opioids is often seen in clinics. drugs, that is, opioid-free drugs that are suboptimal for the monotherapy of amphetamine-type stimulants or opioid dependence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome
  • Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome
  • Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] The percentage by weight of the drug components is: 92% olanzapine, 3% chloracetamide, 5% diphenhydramine, after mixing auxiliary materials such as starch and talcum powder with the above-mentioned drug raw materials, according to the method of the prior art Made into capsules (200 mg each).

Embodiment 2

[0079] The percentage by weight of the drug components is: 85% mirtazapine, 2% lofexidine, 5% scopolamine, 8% flunitrazepam, after mixing the auxiliary materials such as starch and talcum powder with the above-mentioned drug raw materials, according to the existing The method of technology is made into tablets (200 mg each).

Embodiment 3

[0081] The percentage by weight of the drug components: 90% aripiprazole, 5% clofenoxaline, 5% trihexyphenidyl, after mixing the auxiliary materials such as starch and talcum powder with the above-mentioned drug raw materials, it is prepared according to the method of the prior art Into capsules (200 mg per capsule).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome, which comprises the following components in percent by weight: 2-95 percent of antipsychotics, 0.001-5 percent of a2 adrenergic receptor agonist, 0-5 percent of anticholinergic drug, 0-80 percent of non-opiates pain easing agent and 0-10 percent of benzodiazepines drugs. When used for treating symptoms occurring in patients abusing exhilarants of Benzedrine and the like or integrally abusing opioid, the drug achieves better effect, can rapidly and remarkably control abstinence syndrome, and has detoxification cure rate reaching over 90 percent.

Description

technical field [0001] The invention relates to the technical field of medical medicines, in particular to a combined drug for treating amphetamine-type stimulant dependence, amphetamine-type stimulant and opioid mixed dependence. Background technique [0002] At present, the problem of drug abuse is relatively serious. The abused substances include: amphetamine and other stimulants (commonly known as: methamphetamine, ecstasy, K powder, etc.), opioid substances (such as: morphine, heroin, opium tincture, opium, etc.) and so on. There are some therapeutic drugs on the market, but the curative effect is not satisfactory, and all of them can only treat dependence on a certain substance of abuse. However, the problem of multi-drug or multi-substance abuse is common. For example, in my country, in recent years, mixed dependence on amphetamine-type stimulants and opioids is often seen in clinics. Drugs that do not contain opioids are unsatisfactory as monotherapy for the treatmen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/5513A61K31/5517A61P25/30A61P25/36
Inventor 卢正堂张荣
Owner 卢正堂
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com